Board Change • May 20
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. 공시 • May 06
MINAPHARM Pharmaceuticals, Annual General Meeting, Jun 02, 2026 MINAPHARM Pharmaceuticals, Annual General Meeting, Jun 02, 2026, at 15:00 Egypt Standard Time. Location: cairo Egypt 공시 • May 27
MINAPHARM Pharmaceuticals, Annual General Meeting, Jun 18, 2025 MINAPHARM Pharmaceuticals, Annual General Meeting, Jun 18, 2025, at 15:00 Egypt Standard Time. Location: tenth of ramadan Egypt New Risk • May 16
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Egyptian stocks, typically moving 7.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.7x net interest cover). Earnings have declined by 13% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (7.6% average weekly change). Market cap is less than US$100m (ج.م2.34b market cap, or US$46.7m). Board Change • May 14
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. New Risk • Sep 11
New major risk - Revenue and earnings growth Earnings have declined by 2.6% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.4x net interest cover). Earnings have declined by 2.6% per year over the past 5 years. Minor Risk Market cap is less than US$100m (ج.م1.83b market cap, or US$37.8m). Reported Earnings • Jun 04
First quarter 2024 earnings released: EPS: ج.م0.37 (vs ج.م3.49 in 1Q 2023) First quarter 2024 results: EPS: ج.م0.37 (down from ج.م3.49 in 1Q 2023). Revenue: ج.م984.3m (up 1.2% from 1Q 2023). Net income: ج.م4.05m (down 90% from 1Q 2023). Profit margin: 0.4% (down from 4.0% in 1Q 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 29% per year but the company’s share price has increased by 31% per year, which means it is well ahead of earnings. New Risk • Mar 16
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (11% operating cash flow to total debt). High level of non-cash earnings (47% accrual ratio). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Market cap is less than US$100m (ج.م2.88b market cap, or US$60.2m). Valuation Update With 7 Day Price Move • Jan 25
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to ج.م249, the stock trades at a trailing P/E ratio of 6x. Average trailing P/E is 8x in the Pharmaceuticals industry in Egypt. Total returns to shareholders of 219% over the past three years. Valuation Update With 7 Day Price Move • Nov 21
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ج.م238, the stock trades at a trailing P/E ratio of 5.7x. Average trailing P/E is 7x in the Pharmaceuticals industry in Egypt. Total returns to shareholders of 223% over the past three years. Reported Earnings • Aug 31
Second quarter 2023 earnings released: EPS: ج.م7.92 (vs ج.م11.31 in 2Q 2022) Second quarter 2023 results: EPS: ج.م7.92 (down from ج.م11.31 in 2Q 2022). Revenue: ج.م1.07b (up 24% from 2Q 2022). Net income: ج.م87.7m (down 35% from 2Q 2022). Profit margin: 8.2% (down from 16% in 2Q 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has increased by 37% per year, which means it is tracking significantly ahead of earnings growth. Upcoming Dividend • Jun 29
Upcoming dividend of ج.م2.80 per share at 1.3% yield Eligible shareholders must have bought the stock before 06 July 2023. Payment date: 10 July 2023. Payout ratio is a comfortable 6.2% but the company is not cash flow positive. Trailing yield: 1.3%. Lower than top quartile of Egyptian dividend payers (7.5%). Lower than average of industry peers (3.5%). Reported Earnings • Jun 01
First quarter 2023 earnings released: EPS: ج.م3.86 (vs ج.م10.24 in 1Q 2022) First quarter 2023 results: EPS: ج.م3.86 (down from ج.م10.24 in 1Q 2022). Revenue: ج.م972.2m (up 22% from 1Q 2022). Net income: ج.م49.9m (down 60% from 1Q 2022). Profit margin: 5.1% (down from 16% in 1Q 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has increased by 46% per year, which means it is tracking significantly ahead of earnings growth. Valuation Update With 7 Day Price Move • May 22
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to ج.م227, the stock trades at a trailing P/E ratio of 4.3x. Average trailing P/E is 4x in the Pharmaceuticals industry in Egypt. Total returns to shareholders of 261% over the past three years. Reported Earnings • Dec 04
Third quarter 2022 earnings released: EPS: ج.م17.41 (vs ج.م8.40 in 3Q 2021) Third quarter 2022 results: EPS: ج.م17.41 (up from ج.م8.40 in 3Q 2021). Revenue: ج.م984.6m (up 30% from 3Q 2021). Net income: ج.م184.0m (up 80% from 3Q 2021). Profit margin: 19% (up from 14% in 3Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 52% per year but the company’s share price has only increased by 18% per year, which means it is significantly lagging earnings growth. Board Change • Nov 16
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Valuation Update With 7 Day Price Move • Jul 20
Investor sentiment improved over the past week After last week's 16% share price gain to ج.م164, the stock trades at a trailing P/E ratio of 4.4x. Average trailing P/E is 6x in the Pharmaceuticals industry in Egypt. Total returns to shareholders of 118% over the past three years. Upcoming Dividend • Jun 20
Upcoming dividend of ج.م2.92 per share Eligible shareholders must have bought the stock before 27 June 2022. Payment date: 29 June 2022. Payout ratio is a comfortable 7.8% but the company is not cash flow positive. Trailing yield: 1.9%. Lower than top quartile of Egyptian dividend payers (11%). Lower than average of industry peers (4.2%). Valuation Update With 7 Day Price Move • May 31
Investor sentiment improved over the past week After last week's 15% share price gain to ج.م150, the stock trades at a trailing P/E ratio of 4.1x. Average trailing P/E is 6x in the Pharmaceuticals industry in Egypt. Total returns to shareholders of 95% over the past three years. Board Change • Apr 27
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Valuation Update With 7 Day Price Move • Jan 10
Investor sentiment improved over the past week After last week's 18% share price gain to ج.م128, the stock trades at a trailing P/E ratio of 3.5x. Average trailing P/E is 6x in the Pharmaceuticals industry in Egypt. Total returns to shareholders of 75% over the past three years. Upcoming Dividend • May 19
Upcoming dividend of ج.م2.70 per share Eligible shareholders must have bought the stock before 26 May 2021. Payment date: 30 May 2021. Trailing yield: 2.5%. Lower than top quartile of Egyptian dividend payers (8.2%). Lower than average of industry peers (4.2%). Valuation Update With 7 Day Price Move • Apr 28
Investor sentiment improved over the past week After last week's 16% share price gain to ج.م99.28, the stock trades at a trailing P/E ratio of 4.1x. Average trailing P/E is 6x in the Pharmaceuticals industry in Egypt. Total returns to shareholders of 18% over the past three years. Valuation Update With 7 Day Price Move • Apr 07
Investor sentiment deteriorated over the past week After last week's 16% share price decline to ج.م84.88, the stock trades at a trailing P/E ratio of 3.5x. Average trailing P/E is 6x in the Pharmaceuticals industry in Egypt. Total returns to shareholders of 1.0% over the past three years. Reported Earnings • Apr 04
Full year 2020 earnings released The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: ج.م2.36b (up 15% from FY 2019). Net income: ج.م300.8m (up 113% from FY 2019). Profit margin: 13% (up from 6.9% in FY 2019). The increase in margin was driven by higher revenue. Valuation Update With 7 Day Price Move • Feb 08
Investor sentiment improved over the past week After last week's 34% share price gain to ج.م111, the stock is trading at a trailing P/E ratio of 5x, up from the previous P/E ratio of 3.7x. This compares to an average P/E of 6x in the Pharmaceuticals industry in Egypt. Total returns to shareholders over the past three years are 68%. Is New 90 Day High Low • Feb 03
New 90-day high: ج.م86.57 The company is up 15% from its price of ج.م75.13 on 05 November 2020. The Egyptian market is also up 15% over the last 90 days, indicating the company’s price trend is similar to the market over that time. However, it outperformed the Pharmaceuticals industry, which is up 4.0% over the same period. Is New 90 Day High Low • Jan 12
New 90-day high: ج.م85.89 The company is up 15% from its price of ج.م75.00 on 14 October 2020. The Egyptian market is up 5.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is flat over the same period. Reported Earnings • Dec 04
Third quarter 2020 earnings released: EPS ج.م6.32 The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2020 results: Revenue: ج.م590.8m (up 17% from 3Q 2019). Net income: ج.م77.6m (up 247% from 3Q 2019). Profit margin: 13% (up from 4.4% in 3Q 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth. Is New 90 Day High Low • Nov 30
New 90-day high: ج.م80.50 The company is up 4.0% from its price of ج.م77.15 on 01 September 2020. The Egyptian market is up 2.0% over the last 90 days, indicating the company outperformed over that time. However, its price trend is similar to the Pharmaceuticals industry, which is also up 4.0% over the same period. 공시 • Jul 31
Shaheer Wafik Saad El Bardisy acquired an additional 10% stake in MINAPHARM Pharmaceuticals (CASE:MIPH) for approximately EGP 100 million. Shaheer Wafik Saad El Bardisy acquired an additional 10% stake in MINAPHARM Pharmaceuticals (CASE:MIPH) for approximately EGP 100 million on July 26, 2020. Shaheer Wafik Saad El Bardisy bought 1.2 million shares and increased his stake to 10.89%.
Shaheer Wafik Saad El Bardisy completed the acquisition of an additional 10% stake in MINAPHARM Pharmaceuticals (CASE:MIPH) on July 26, 2020.